X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8434) 8434
Newspaper Article (782) 782
Publication (680) 680
Newsletter (106) 106
Book Review (100) 100
Book Chapter (91) 91
Book / eBook (74) 74
Magazine Article (37) 37
Web Resource (30) 30
Trade Publication Article (22) 22
Dissertation (13) 13
Conference Proceeding (10) 10
Data Set (4) 4
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5255) 5255
esophagus (4507) 4507
male (3813) 3813
index medicus (3155) 3155
female (3126) 3126
animals (2410) 2410
middle aged (2217) 2217
cancer (1896) 1896
esophagus - drug effects (1848) 1848
adult (1829) 1829
oncology (1715) 1715
aged (1682) 1682
gastroenterology & hepatology (1595) 1595
esophageal cancer (1066) 1066
gastroesophageal reflux (1055) 1055
surgery (1048) 1048
research (978) 978
patients (967) 967
care and treatment (877) 877
esophagus - pathology (843) 843
studies (805) 805
chemotherapy (801) 801
medicine (798) 798
tumors (792) 792
barretts-esophagus (777) 777
rats (759) 759
adenocarcinoma (755) 755
esophagus - physiology (748) 748
risk factors (747) 747
esophageal neoplasms - pathology (727) 727
cancer therapies (678) 678
endoscopy (677) 677
apoptosis (669) 669
research article (667) 667
treatment outcome (663) 663
health aspects (644) 644
gene expression (616) 616
proteins (616) 616
metastasis (602) 602
barrett's esophagus (586) 586
medical prognosis (582) 582
expression (564) 564
esophagus - metabolism (562) 562
analysis (544) 544
aged, 80 and over (543) 543
esophageal neoplasms - drug therapy (527) 527
multidisciplinary sciences (521) 521
gastroenterology (517) 517
diagnosis (508) 508
cell line, tumor (502) 502
science (491) 491
squamous cell carcinoma (490) 490
disease (480) 480
time factors (472) 472
esophagus - physiopathology (467) 467
hydrogen-ion concentration (466) 466
mice (466) 466
prognosis (447) 447
medical research (440) 440
pharmacology & pharmacy (439) 439
physiology (436) 436
genetic aspects (431) 431
gastroesophageal reflux - drug therapy (419) 419
therapy (419) 419
manometry (415) 415
dose-response relationship, drug (411) 411
development and progression (394) 394
muscle contraction - drug effects (390) 390
biopsy (387) 387
kinases (387) 387
stomach (384) 384
in vitro techniques (379) 379
gastroesophageal-reflux disease (378) 378
barrett esophagus - pathology (370) 370
pressure (369) 369
carcinoma (367) 367
physiological aspects (364) 364
proton pump inhibitors (363) 363
clinical trials (362) 362
muscle, smooth - drug effects (355) 355
immunohistochemistry (354) 354
acids (347) 347
prospective studies (347) 347
mortality (339) 339
esophageal neoplasms - metabolism (338) 338
hospitals (335) 335
inflammation (333) 333
squamous-cell carcinoma (329) 329
adolescent (328) 328
cell cycle (324) 324
breast cancer (321) 321
cell growth (319) 319
esophageal neoplasms - genetics (316) 316
survival (316) 316
adenocarcinoma - pathology (313) 313
lung cancer (309) 309
drug therapy (306) 306
drug dosages (305) 305
usage (301) 301
retrospective studies (300) 300
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (56) 56
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
St. Michael's Hospital - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Robarts - Stacks (2) 2
Credit Valley Hospital - Reference (1) 1
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Reference (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
OISE - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St Josephs Health Centre - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9119) 9119
Russian (107) 107
German (87) 87
French (64) 64
Japanese (56) 56
Chinese (43) 43
Italian (30) 30
Spanish (27) 27
Portuguese (10) 10
Dutch (8) 8
Hungarian (7) 7
Polish (5) 5
Norwegian (4) 4
Swedish (4) 4
Ukrainian (4) 4
Danish (3) 3
Korean (3) 3
Turkish (3) 3
Bulgarian (2) 2
Czech (2) 2
Romanian (2) 2
Serbian (2) 2
Arabic (1) 1
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular and Cellular Biology, ISSN 0270-7306, 06/2010, Volume 30, Issue 12, pp. 3016 - 3026
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2181 - 2190
Journal Article
Journal Article
Nature Materials, ISSN 1476-1122, 10/2015, Volume 14, Issue 10, pp. 1065 - 1071
Devices resident in the stomach-used for a variety of clinical applications including nutritional modulation for bariatrics, ingestible electronics for... 
PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | BIOENTERICS INTRAGASTRIC BALLOON | RESIDENCE | RETENTION | MATERIALS SCIENCE, MULTIDISCIPLINARY | DOGS | CHEMISTRY, PHYSICAL | DOSAGE FORMS | BOND | DRUG-DELIVERY SYSTEMS | RELEASE COATINGS | Stomach | Biomedical materials | Drug delivery systems | Hydrogels | Polymers | Drugs | Modulation | Elastomers | Electronics | Risk | Devices | Dissolution
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1467 - 1482
Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess... 
CELL LUNG-CANCER | OVEREXPRESSION | AMPLIFICATION | ONCOLOGY | ONARTUZUMAB | ADENOCARCINOMA | HEPATOCYTE GROWTH-FACTOR | C-MET | RECEPTOR | AMG 102 | EXPRESSION | Capecitabine - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Esophageal Neoplasms - mortality | Adult | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Proto-Oncogene Proteins c-met - drug effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Disease-Free Survival | Capecitabine - adverse effects | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Survival Analysis | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Epirubicin - adverse effects | Clinical trials | Monoclonal antibodies | Anthracyclines | Product development | Esophageal cancer | Analysis
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1512 - 1522
Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour... 
HETEROGENEITY | EMTANSINE | THERAPY | ONCOLOGY | CANCER AMERICAN SOCIETY | CLINICAL-PRACTICE GUIDELINE | GENE AMPLIFICATION | JUNCTION CANCER | HER2 STATUS | OPEN-LABEL | PLUS PACLITAXEL | Breast Neoplasms - surgery | Prognosis | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Mastectomy - methods | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Patient Safety | Esophageal Neoplasms - mortality | Immunoconjugates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Receptor, ErbB-2 - drug effects | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - genetics | Esophageal Neoplasms - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Antimitotic agents | Care and treatment | Safety and security measures | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Tumors | Enzymes | Medical research | Analysis | Medicine, Experimental | Health aspects
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133349
Esophageal squamous cell carcinomas (ESCC) have become a severe threat to health and the current treatments for ESCC are frequently not effective. Recent... 
CANCER-CELLS | PROSTATE | APOPTOSIS | CISPLATIN | ANGIOGENESIS | SIGNALING PATHWAY | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | RESISTANCE | PROLIFERATION | INDUCTION | Cyclin D1 - metabolism | AMP-Activated Protein Kinases - metabolism | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Male | Esophageal Neoplasms - pathology | Cyclin-Dependent Kinase Inhibitor p27 - metabolism | Esophageal Neoplasms - metabolism | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Cell Survival - drug effects | Metformin - pharmacology | Tumor Suppressor Protein p53 - metabolism | Enzyme Activation - drug effects | Blotting, Western | Hypoglycemic Agents - pharmacology | Xenograft Model Antitumor Assays | Animals | Carcinoma, Squamous Cell - drug therapy | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Resting Phase, Cell Cycle - drug effects | Cell Proliferation - drug effects | G1 Phase Cell Cycle Checkpoints - drug effects | Esophageal Neoplasms - drug therapy | Diabetics | Squamous cell carcinoma | Growth | Cell cycle | Metformin | Tumor proteins | Health aspects | Esophageal cancer | Flow cytometry | Regulations | p53 Protein | Colorectal cancer | Kinases | Epidemiology | Anticancer properties | Angiogenesis | Cell activation | Cell growth | Gastroenterology | Xenografts | Tumorigenesis | Inhibition | Growth factors | G1 phase | Esophageal carcinoma | Enzymes | Adenosine | Diabetes mellitus | Cyclin-dependent kinases | Health risks | Risk reduction | Cell division | Cultures | Metabolism | Esophagus | Cyclin-dependent kinase inhibitor p21 | Hospitals | Cell lines | Cyclin-dependent kinase inhibitor p27 | Antitumor activity | Hypoxia | Cancer
Journal Article
Oncology Reports, ISSN 1021-335X, 10/2014, Volume 32, Issue 4, pp. 1748 - 1756
Esophageal squamous cell carcinoma (ESCC) is an aggressive tumor with high incidence and mortality worldwide. Diallyl disulfide (DADS) is a natural... 
MEK-ERK | G2/M | apoptosis | diallyl disulfide | p53/p21 | Diallyl disulfide | Apoptosis | ACTIVATION | MCF-7 | CYCLE ARREST | PROLIFERATION | HUMAN GASTRIC-CANCER | DAMAGE | SULFIDE | INHIBITION | ONCOLOGY | CDC2 Protein Kinase | Cyclin-Dependent Kinases - metabolism | Apoptosis - drug effects | Humans | RNA, Messenger - metabolism | cdc25 Phosphatases - drug effects | Cyclin-Dependent Kinases - drug effects | G2 Phase Cell Cycle Checkpoints - drug effects | Esophageal Neoplasms | Disulfides - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cyclin-Dependent Kinases - genetics | Esophageal Squamous Cell Carcinoma | RNA, Messenger - drug effects | Cell Survival - drug effects | Tumor Suppressor Protein p53 - metabolism | Cyclin B1 - genetics | cdc25 Phosphatases - genetics | Allyl Compounds - pharmacology | Tumor Suppressor Protein p53 - drug effects | Carcinoma, Squamous Cell | rho GTP-Binding Proteins - drug effects | Cyclin B1 - drug effects | MAP Kinase Signaling System - drug effects | Signal Transduction - drug effects | rho GTP-Binding Proteins - metabolism | Cell Line, Tumor | Drug Screening Assays, Antitumor | Sulfur compounds | Care and treatment | Squamous cell carcinoma | Genetic aspects | Esophageal cancer | Testing | Phosphorylation | Chemotherapy | Cell cycle | Software | Experiments | Cancer therapies | Esophagus | Index Medicus
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 08/2017, Volume 490, Issue 3, pp. 1112 - 1118
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 03/2012, Volume 11, Issue 3, pp. 763 - 774
Esophageal adenocarcinomas are poorly responsive to chemotherapeutics. This study aimed to determine the levels of Aurora kinase A (AURKA) and the therapeutic... 
OVEREXPRESSION | PROTEIN | CARCINOGENESIS | ONCOLOGY | C-MYC | CARCINOMAS | DYSPLASIA | BARRETTS-ESOPHAGUS | NF-KAPPA-B | CANCER | PROGRESSION | Esophagus - drug effects | Gene Expression - drug effects | Apoptosis - drug effects | Humans | Aurora Kinase A | Proto-Oncogene Proteins c-bcl-2 - metabolism | Adenocarcinoma - metabolism | Esophageal Neoplasms - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Apoptosis Regulatory Proteins - genetics | Female | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Cell Line | Cell Survival - drug effects | Protein-Serine-Threonine Kinases - genetics | Esophagus - metabolism | Proto-Oncogene Proteins - genetics | Aurora Kinases | Cisplatin - pharmacology | Pyrimidines - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Adenocarcinoma - drug therapy | Blotting, Western | Apoptosis Regulatory Proteins - metabolism | Azepines - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Esophagus - pathology | Animals | Esophageal Neoplasms - genetics | Cell Cycle Checkpoints - drug effects | Mice, Nude | Cell Line, Tumor | Mice | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-bcl-2 - genetics | Esophageal | Mitosis | p73 | Cisplatin | AURKA | Barrett’s | Cancer | Apoptosis | p53
Journal Article
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2013, Volume 19, Issue 8, pp. 1005 - 1013
Journal Article